Haemonetics CorpHAE
Price$104.37Intrinsic value$73.4930% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $73.49median of 6 methods · middle span $69-$82based on filings through 27 Jun 2026
Market Price $104.37Price as of 1 Oct 2026
Margin of Safety -29.6%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 10.0% (near-term consensus, capped) · years 2–5: 8.3%/yr (balance of the path).8.7% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 67.8%Yr 77.3%Yr 86.8%Yr 96.3%Yr 105.8%
8.3% → 5.8%
Years 11–20: glide to long-run rate
Per-year rates
Yr 115.5%Yr 125.2%Yr 134.9%Yr 144.7%Yr 154.4%Yr 164.1%Yr 173.8%Yr 183.6%Yr 193.3%Yr 203.0%
5.8% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)5.8%
Discount rate (cost of equity) 8.1%
Volatility vs market (adjusted beta)0.69

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetHaemonetics CorpHAEHealth Care
Valuation
P/E50.4×
P/S3.6×
P/B5.8×
EV / Revenue4.3×
EV / EBITDA17.0×
Profitability
Gross margin59.0%
Operating margin11.7%
Net margin7.1%
FCF margin21.5%
Returns
ROE11.5%
ROA4.1%
ROIC5.4%
Growth
Revenue growth (YoY)-0.6%
5-yr fwd EPS growth8.7%
Financial strength
Debt / Equity1.40×
Current ratio3.08×
Altman Z-Score3.2
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.